HIGHFDA DRUG

Glenmark Carvedilol Tablets Recalled Over Nitrosamine Impurity

Glenmark Pharmaceuticals Inc. recalls 6,432 bottles of Carvedilol Tablets, USP, 12.5 mg, distributed nationwide in the United States. The recall concerns CGMP deviations and the presence of a nitrosamine impurity above the acceptable intake level. Consumers should stop taking the product and contact Glenmark for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
August 7, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
August 7, 2025
Hazard Level
HIGH
Brand
Glenmark Pharmaceuticals Inc.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT, ELDERLY

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Glenmark Pharmaceuticals Inc.
Product type
Carvedilol Tablets
Model numbers
Lot#:19243202, Exp: 7/31/2026
UPC codes
68462-162, 68462-163, 68462-164, 68462-165, 68462-162-60, 68462-162-01, 68462-162-18, 68462-162-05 +6 more
Sizes
12.5 mg
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    August 7, 2025

  2. Reported by FDA DRUG

    August 20, 2025

  3. RecallRadar source check

    April 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Glenmark Pharmaceuticals Inc., USA or your healthcare provider for guidance. Notification method: Letter

About This Product

Carvedilol tablets are a beta-blocker used to treat high blood pressure and heart failure. They are prescribed by physicians and dispensed by pharmacies.

Why This Is Dangerous

Nitrosamine impurities are potential carcinogens. Elevated levels in carvedilol could pose long-term health risks with chronic exposure.

Industry Context

This recall is not described as part of a broader industry pattern in the notice.

Real-World Impact

Immediate stop-use is required. Patients may need to switch therapies and manage supply through healthcare providers.

Practical Guidance

How to identify if yours is affected

  1. Check Lot#: 19243202 and Exp: 7/31/2026.
  2. Confirm bottle is a 500-count carvedilol tablet bottle, 12.5 mg.

Where to find product info

NDC on bottle label; lot code and expiry printed on the bottle

What timeline to expect

Refunds or replacement details will be provided via recall communications; expect weeks for processing

If the manufacturer is unresponsive

  • Contact FDA consumer complaint portal
  • Reach out to Glenmark Pharmaceuticals, Inc., USA for escalation

How to prevent similar issues

  • Check for CGMP deviations in all prescription medications during recalls
  • Verify NDC numbers and lot codes before safekeeping new prescriptions
  • Consult pharmacist if unsure about a product's recall status

Documentation advice

Keep copy of recall notice, bottle label, lot number, expiry, and any correspondence with the company

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

NDC 68462-164-05. 12.5 mg carvedilol tablets, 500-count bottles. Manufactured by Glenmark Pharmaceuticals Ltd., Colvale-Bardez, Goa, India. Distributed by Glenmark Pharmaceuticals, Inc., USA, Mahwah, NJ 07430. Quantity: 6,432 bottles. Sold nationwide in the USA. Expiry seen on lot: 7/31/2026. Lot number: 19243202.

Reported Incidents

No specific patient injuries or adverse events are reported in the recall notice. The FDA enforcement listing indicates a high-hazard impurity concern.

Key Facts

  • Manufactured in India for Glenmark Pharmaceuticals, Inc., USA

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTELDERLYPREGNANT
Injury Types
POISONINGLACERATION

Product Details

Model Numbers
Lot#:19243202
Exp: 7/31/2026
UPC Codes
68462-162
68462-163
68462-164
+11 more
Affected States
ALL
Report Date
August 20, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls